Insights

Gathering insights about Cogent…

Similar companies to Cogent

Cogent Tech Stack

Cogent uses 8 technology products and services including Crazy Egg, Babel, Google Maps, and more. Explore Cogent's tech stack below.

Crazy Egg
Analytics
Babel
Development
Google Maps
Maps
Microsoft
Miscellaneous
MediaElement.js
Video Players
YouTube
Video Players
HTTP/3
Web & Portal Technology
Adobe Fonts
Web Fonts

Media & News

Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy'
Cogent Biosciences, Inc. maintains a Buy rating as bezuclastinib demonstrates blockbuster potential in GIST and systemic mastocytosis (SM) indications. Bezuclastinib nearly doubled median PFS in 2L GIST (PEAK trial), supporting a high peak market share assumption despite competitive pressures. COGT's sum-of-the-parts valuation yields a fair value of $26.54/share, with current cash reserves likely sufficient to reach commercial launch, though dilution risk remains.
Apr 02, 2026 | seekingalpha.com
Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP)
Cogent Biosciences (NASDAQ: COGT - Get Free Report) and GT Biopharma (NASDAQ: GTBP - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership. Analyst Ratings This is a breakdown of recent
Apr 02, 2026 | www.defenseworld.net
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
WALTHAM, Mass. and BOULDER, Colo., April 01, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib. Based on the positive results from the PEAK trial, the bezuclastinib NDA was submitted under the FDA's Real-Time Oncology Review (RTOR) program, which is intended to enable a more streamlined review process. Bezuclastinib was also granted Breakthrough Therapy Designation as a treatment for GIST earlier this year.
Apr 01, 2026 | www.globenewswire.com
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
UBS analysts have outlined a set of high-conviction healthcare ideas where they believed the market was underappreciating earnings durability and the scale of upcoming catalysts, focusing on stocks backed by differentiated views and proprietary insights. In biotechnology, they identified Cogent Biosciences (NASDAQ:COGT) as their top pick, arguing the company offered scarcity value as a SMID-cap advancing two late-stage, potentially blockbuster assets.
Mar 30, 2026 | www.proactiveinvestors.com
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
RTW Investments added 4,124,755 Cogent Biosciences shares in the fourth quarter; the estimated trade size was $115.95 million. Meanwhile, the quarter-end stake value increased by $219.88 million, reflecting both trading and price appreciation.
Mar 21, 2026 | www.fool.com
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
Kynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million. Meanwhile, the position's quarter-end value changed by $105.74 million, reflecting both trading and share price movements.
Mar 21, 2026 | www.fool.com
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
Boone Capital Management sold 945,042 shares of Cogent Biosciences in the fourth quarter. As a result, the quarter-end position value decreased by $13.57 million.
Mar 20, 2026 | www.fool.com

Cogent's Email Address Formats

Cogent uses at least 1 format(s):

Cogent Email Formats	Example	Percentage
First.Last@cogent.co.uk	John.Doe@cogent.co.uk	49%
Last@cogent.co.uk	Doe@cogent.co.uk	1%
FirLast@cogent.co.uk	JohDoe@cogent.co.uk	1%
First.Last@cogent.co.uk	John.Doe@cogent.co.uk	49%

Frequently Asked Questions

Where is Cogent's headquarters located?

Cogent's main headquarters is located at Royal Leamington Spa, England cv31 3ne United Kingdom. The company has employees across 4 continents, including EuropeAsiaNorth America.

What is Cogent's stock symbol?

Cogent is a publicly traded company; the company's stock symbol is COGT.

What is Cogent's official website and social media links?

Cogent's official website is cogent.co.uk and has social profiles on LinkedIn.

What is Cogent's SIC code NAICS code?

Cogent's SIC code is 8742 - Management Consulting Services NAICS code is 541613 - Marketing Consulting Services.

How many employees does Cogent have currently?

As of March 2026, Cogent has approximately 175 employees across 4 continents, including EuropeAsiaNorth America. Key team members include Chief Executive Officer Of The Cogent Group: I. G.Head Of Pr: H. H.Head Of Design: S. A.. Explore Cogent's employee directory with LeadIQ.

What industry does Cogent belong to?

Cogent operates in the Advertising Services industry.

What technology does Cogent use?

Cogent's tech stack includes Crazy EggBabelGoogle MapsMicrosoftMediaElement.jsYouTubeHTTP/3Adobe Fonts.

What is Cogent's email format?

Cogent's email format typically follows the pattern of First.Last@cogent.co.uk. Find more Cogent email formats with LeadIQ.

When was Cogent founded?

Cogent was founded in 1930.

Cogent

Q: What is Cogent's official website and social media links?

Cogent's official website is cogent.co.uk. Cogent has social profiles on LinkedIn.

Q: How many employees does Cogent have currently?

Cogent has approximately 175 employees.

Q: What technology does Cogent use?

Cogent's tech stack includes Cloudflare, Google Fonts API, Modernizr, jQuery Migrate, JSON-LD.

Advertising ServicesEngland, United Kingdom51-200 Employees

If nobody notices your advertising, is it even advertising?

People see around 360 ads every day. Most are skipped, scrolled, flicked or walked past. Blah-vertising. Meh-vertising. Beige-vertising.

It’s time to ban bland insights. Cull dull copy. Banish boring design. And give beige a good poke in the eye.